The size of the Asia Pacific aptamers market has been forecasted at USD 50.15 million in 2023 and will reach USD 138.34 million by the end of 2028, scoring a CAGR of 22.5% between 2023 to 2028.
The growth of the aptamers market in the APAC region is expected to be driven by the aptamer's benefits over antibodies, such as cheap cost and high efficiency, and the range of applications available. Also, market growth is projected to be boosted by continuous technological advancements and their fast implementation throughout the forecast period. Major companies have been making a significant impact in the market in the past few years. Also, introducing a chemical modification technique to improve aptamers' nuclease resistance and therapeutic characteristics boosts the market growth. In addition, the growing amount of research and development (R & R&D) efforts done for developing diagnostic equipment, medicines, and their carriers can also be attributed to the market of aptamers.
The increase of R&D investments is likely to have a favorable influence on market growth. Aptagen, a major participant in the industry, has been developing aptamers for more than 25 years. The company has been developing aptamers for proteins, small molecules, tissues, and cells that are particularly binding and high affinity. In addition, the firm manufactures cutting-edge and innovative components for medicines, bio-industrial, and diagnostic applications. During the forecast period, these trends and developments are likely to influence the market.
On the other hand, the proliferation of life-threatening diseases such as cancer, cardiovascular diseases, AIDS, and neurodegenerative disorders majorly influences the demand for effective assays based on Aptamer therapy. Apart from that, these small molecules offer various advantages in contrast to known antibodies that have led to increased demand for these molecules across a wide variety of medicinal applications. For example, they're chemically produced, so there's no batch-to-batch variance, and development takes less time.
Furthermore, private companies collaborate with academic institutions and research labs to offer next-generation products and enhance their market presence. Aptamers are expected to be used in a wide range of medical therapies and the food and beverage (F&B) sector as a result of this.
However, a lack of skilled professionals may hamper the market growth during the given period. Furthermore, the manufacturers have chosen to avoid using these molecules due to a lack of understanding of aptamers and technical expertise.
This research report segmented and sub-segmented the Asia Pacific Aptamers Market into the following categories:
By End User:
Geographically, the APAC is one of the fastest-growing regions in the global aptamers market over the years. It is projected to account for a remarkable share in the global market during the forecast period owing to access to optimum treatment facilities, increasing healthcare spending, and better adoption of technologies. Further, increasing demand for Aptamers, favorable government policies, and the increasing trend of R&D in pharmaceutical and biotechnological industries are fuelling the market growth.
The Chinese aptamers market dominated the APAC aptamers market in 2020 and is estimated to account for the most significant share during the forecast period. The market is more likely to continue its growth throughout the forecast period. China witnessed technological advancements in the healthcare sector owing to the increasing investment and funding by the government.
On the other hand, the Indian Aptamers market is anticipated to record a promising share and contribute to the APAC regional market during the forecast period. Supportive government policies, improving healthcare infrastructure, and ongoing research & development activities have led to adopting Aptamers, leading to market growth.
KEY MARKET PLAYERS:
Companies playing a notable role in the APAC aptamers market are AM Biotechnologies, Aptagen, Aptamer Sciences Inc., Aptamer Solutions Ltd., Aptus Biotech S.L., Base Pair Biotechnologies Inc., NeoVentures Biotechnology Inc., SomaLogic Inc, TriLink BioTechnologies Inc., and Vivonics, Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org